SynAct Pharma’s 2025 year-end report highlights a year of clinical execution and strategic expansion. With recruitment now complete for the phase IIb ADVANCE study in rheumatoid arthritis and the RESPIRE trial underway, the company is approaching transformative clinical readouts for resomelagon. BioStock contacted CEO Jeppe Øvlesen for a comment.
Read the full interview at biostock.se:
Topline results on the horizon for SynAct Pharma
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/